secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2026-05-14T20:01:25+00:00
Accession:  0001401914-26-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience reports Q1 2026 cash $18.5M; first product revenue expected June 2026
--------------------------------------------------------------------------------

- Cash and equivalents $18.5M as of March 31; working capital ~$0.5M; revenue $0.2M from Gates Foundation services.
- Ovaprene Phase 3 trial receives second positive DSMB review; enrollment expected to complete in 2026 with 2027 primary endpoint analysis.
- DARE to PLAY sildenafil cream dispensing to commence summer 2026; pre-fulfillment prescribing active in all 50 states.
- Flora Sync LF5 commercial launch in June 2026; first-ever product revenue milestone expected that month.
- DARE-HPV Phase 2 study starting May 2026 with ARPA-H funding; DARE to RECLAIM targeting 2027 dispensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/0001401914-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/dare-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001401914-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer